Abstract |
In T-cell Acute Lymphocytic Leukemia ( T-ALL), the inhibitors of cyclin-dependent kinases (CDK) 4 and 6, p16 and p15, are inactivated almost universally at the DNA, RNA and protein levels. This suggests that CDK-targeting may be an effective therapeutic approach for T-ALL and other cancers. In this study, we tested 3 inhibitors of CDK4, 3-aminothioacridone (3-ATA), thioacridone (TA), and oxindole, for their effects on DNA synthesis and viability in primary T-ALL. Each compound was an effective inhibitor, with overall IC(50)s in similar ranges. In colony formation assay, leukemic cells were approximately 10-fold more sensitive to 3-ATA than normal bone marrow cells. When sorted by G1 protein status of T-ALL, p16(+), p15(+) or pRb(-) samples were significantly less sensitive to 3-ATA and TA, but not to oxindole, than p16(-), p15(-) or pRb(+) samples. There was no relationship of sensitivity with ARF expression. Despite their in vitro function as inhibitors of CDK4, 3-ATA did not inhibit pRb phosphorylation or cause G1 arrest, but did cause DNA damage and result in the induction and phosphorylation of p53. We conclude that 3-ATA efficacy can be predicted by p16 status in T-ALL, but the mechanism of action may be distinct from their in vitro ability to regulate CDK4 kinase activity
|
Authors | Mitchell B Diccianni, John Yu, Gerda Meppelink, Marten de Vries, Lien Shao, Sigrun Gebauer, Hsien Shih, William Roberts, Neil P Kilcoin, Jeanette Pullen, Dennis A Carson, Alice L Yu |
Journal | Journal of experimental therapeutics & oncology
(J Exp Ther Oncol)
Vol. 4
Issue 3
Pg. 223-37
(Oct 2004)
ISSN: 1359-4117 [Print] United States |
PMID | 15724842
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 3-aminothioacridone
- Aminoacridines
- Enzyme Inhibitors
- Proto-Oncogene Proteins
- DNA
- CDK4 protein, human
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinases
|
Topics |
- Aminoacridines
(pharmacology)
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinases
(antagonists & inhibitors, pharmacology)
- DNA
(biosynthesis)
- DNA Damage
(drug effects)
- Enzyme Inhibitors
(pharmacology)
- Genes, p16
- Genes, p53
- Humans
- Leukemia-Lymphoma, Adult T-Cell
(genetics, pathology)
- Prognosis
- Proto-Oncogene Proteins
(antagonists & inhibitors, pharmacology)
- Treatment Outcome
|